Three decades of β-lactamase inhibitors

Clinical Microbiology Reviews

Volumn 23, Issue 1, 2010, Pages 160-201

  Drawz, Sarah M ^a   Bonomo, Robert A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 METHYL 1,2,3 TRIAZOL 4 YLMETHYLENE)PENEM 3 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; BAL 19764; BAL 29880; BAL 30072; CARBAPENEM DERIVATIVE; CEFOTETAN; CEFPIROME; CEFTAZIDIME; CLAVULANIC ACID; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PENAM DERIVATIVE; PENEM DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SIDEROPHORE; SULBACTAM; SULFONE; SULTAMICILLIN; SYN 2190; TAZOBACTAM; TIMENTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL INFECTION; APPENDICITIS; ASPIRATION PNEUMONIA; BINDING SITE; BONE INFECTION; CHEMICAL STRUCTURE; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT INFECTION; DRUG MECHANISM; ENDOMETRITIS; ENZYME INHIBITION; ENZYMOLOGY; GRAM NEGATIVE INFECTION; GYNECOLOGIC INFECTION; HUMAN; HYDROLYSIS; INFECTION; INFECTIOUS ARTHRITIS; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; OTITIS MEDIA; PELVIC INFLAMMATORY DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SEPTICEMIA; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; TOOTH ABSCESS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ENZYME INHIBITORS; HUMANS;

EID: 74249108028     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00037-09     Document Type: Review

References (464)

1. Abraham, E. P., and E. Chain. 1940. An enzyme from bacteria able to destroy penicillin. Nature 146:837.
2. Abraham, E. P., E. Chain, C. M. Fletcher, H. W. Florey, A. D. Gardner, N. G. Heatley, and M. A. Jennings. 1941. Further observations on penicillin. Lancet ii:177.
3. Adachi, H., T. Ohta, and H. Matsuzawa. 1991. Site-directed mutants, at position 166, of RTEM-1 β-lactamase that form a stable acyl-enzyme intermediate with penicillin. J. Biol. Chem. 266:3186-3191.
4. Adediran, S. A., M. Nukaga, S. Baurin, J. M. Frere, and R. F. Pratt. 2005. Inhibition of class D β-lactamases by acyl phosphates and phosphonates. Antimicrob. Agents Chemother. 49:4410-4412.
5. Adediran, S. A., and R. F. Pratt. 2008. Inhibition of serine β-lactamases by vanadate-catechol complexes. Biochemistry 47:9467-9474.
6. Afzal-Shah, M., N. Woodford, and D. M. Livermore. 2001. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45:583-588.
7. Akova, M. 2008. Sulbactam-containing β-lactamase inhibitor combinations. Clin. Microbiol. Infect. 14(Suppl. 1):185-188.
8. Akova, M., Y. Yang, and D. M. Livermore. 1990. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I β-lactamases. J. Antimicrob. Chemother. 25:199-208.
9. Alonso, R., G. Gerbaud, M. Galimand, and P. Courvalin. 2002. TEM-103/ IRT-28 β-lactamase, a new TEM variant produced by Escherichia coli BM4511. Antimicrob. Agents Chemother. 46:3627-3629.
10. Ambler, R. P., A. F. Coulson, J. M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276:269-270.
11. Anderson, S. D., and J. G. Gums. 2008. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann. Pharmacother. 42:806-816.
12. Angus, B. L., A. M. Carey, D. A. Caron, A. M. Kropinski, and R. E. Hancock. 1982. Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrob. Agents Chemother. 21:299-309.
13. Atanasov, B. P., D. Mustafi, and M. W. Makinen. 2000. Protonation of the β-lactam nitrogen is the trigger event in the catalytic action of class A β-lactamases. Proc. Natl. Acad. Sci. U. S. A. 97:3160-3165.
14. Babic, M., A. M. Hujer, and R. A. Bonomo. 2006. What's new in antibiotic resistance? Focus on β-lactamases. Drug Resist. Updat. 9:142-156.
15. Babini, G. S., and D. M. Livermore. 2000. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC β-lactamases. J. Antimicrob. Chemother. 45:105-109.
16. Bantar, C., E. Vesco, C. Heft, F. Salamone, M. Krayeski, H. Gomez, M. A. Coassolo, A. Fiorillo, D. Franco, C. Arango, F. Duret, and M. E. Oliva. 2004. Replacement of broad-spectrum cephalosporins by piperacillintazobactam: impact on sustained high rates of bacterial resistance. Antimicrob. Agents Chemother. 48:392-395.
17. Bassetti, M., E. Righi, and C. Viscoli. 2008. Novel β-lactam antibiotics and inhibitor combinations. Expert Opin. Invest. Drugs 17:285-296.
18. Bauernfeind, A., J. M. Casellas, M. Goldberg, M. Holley, R. Jungwirth, P. Mangold, T. Rohnisch, S. Schweighart, and R. Wilhelm. 1992. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection 20:158-163.
19. Bauvois, C., and J. Wouters. 2007. Crystal structures of class C β-lactamases: mechanistic implications and perspectives in drug design, p. 145-161. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
20. Bayles, K. W. 2000. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol. 8:274-278.
21. Beadle, B. M., and B. K. Shoichet. 2002. Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob. Agents Chemother. 46: 3978-3980.
22. Beesley, T., N. Gascoyne, V. Knott-Hunziker, S. Petursson, S. G. Waley, B. Jaurin, and T. Grundstrom. 1983. The inhibition of class C β-lactamases by boronic acids. Biochem. J. 209:229-233.
23. Belaaouaj, A., C. Lapoumeroulie, M. M. Canica, G. Vedel, P. Nevot, R. Krishnamoorthy, and G. Paul. 1994. Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol. Lett. 120:75-80.
24. Bennett, P. M., and I. Chopra. 1993. Molecular basis of β-lactamase induction in bacteria. Antimicrob. Agents Chemother. 37:153-158.
25. Bethel, C. R., A. M. Distler, M. W. Ruszczycky, M. P. Carey, P. R. Carey, A. M. Hujer, M. Taracila, M. S. Helfand, J. M. Thomson, M. Kalp, V. E. Anderson, D. A. Leonard, K. M. Hujer, T. Abe, A. M. Venkatesan, T. S. Mansour, and R. A. Bonomo. 2008. Inhibition of OXA-1 β-lactamase by penems. Antimicrob. Agents Chemother. 52:3135-3143.
26. Bitha, P., Z. Li, G. D. Francisco, B. A. Rasmussen, and Y. I. Lin. 1999. 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C β-lactamases. I. Bioorg. Med. Chem. Lett. 9:991-996.
27. Bitha, P., Z. Li, G. D. Francisco, Y. Yang, P. J. Petersen, E. Lenoy, and Y. I. Lin. 1999. 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C β-lactamases. II. Bioorg. Med. Chem. Lett. 9:997-1002. 28. Black, J. A., K. S. Thomson, J. D. Buynak, and J. D. Pitout. 2005. Evaluation of β-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC β-lactamases in well-characterized clinical strains of Klebsiella spp. J. Clin. Microbiol. 43:4168-4171.
28. Blazquez, J., M. R. Baquero, R. Canton, I. Alos, and F. Baquero. 1993. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob. Agents Chemother. 37:2059-2063.
29. Bone, R., A. B. Shenvi, C. A. Kettner, and D. A. Agard. 1987. Serine protease mechanism: structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid. Biochemistry 26:7609-7614.
30. Bonnefoy, A., C. Dupuis-Hamelin, V. Steier, C. Delachaume, C. Seys, T. Stachyra, M. Fairley, M. Guitton, and M. Lampilas. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417.
31. Bonnet, R. 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.
32. Bonomo, R. A., C. Currie-McCumber, and D. M. Shlaes. 1992. OHIO-1 β-lactamase resistant to mechanism-based inactivators. FEMS Microbiol. Lett. 71:79-82.
33. Bonomo, R. A., J. Liu, Y. Chen, L. Ng, A. M. Hujer, and V. E. Anderson. 2001. Inactivation of CMY-2 β-lactamase by tazobactam: initial mass spectroscopic characterization. Biochim. Biophys. Acta 1547:196-205.
34. Bonomo, R. A., and L. B. Rice. 1999. Inhibitor resistant class A β-lactamases. Front. Biosci. 4:e34-41.
35. Bonomo, R. A., S. A. Rudin, and D. M. Shlaes. 1997. Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases. FEMS Microbiol. Lett. 148:59-62.
36. Bowker, K. E., A. R. Noel, and A. P. MacGowan. 2007. A monobactam plus double β-lactamase inhibitor combination (BAL 30376) designed to overcome multiple resistance in gram negative bacilli: proof of concept in an in vitro pharmacokinetic model, abstr. F1-314. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
37. Bowker, K. E., T. R. Walsh, and A. P. MacGowan. 2009. In vitro activity of a new siderophore monobactam BAL 30072 against ESBL-producing Enterobacteriacae and clinical isolates of Enterobacter cloacae, abstr. P1112. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland.
38. Bowler, L. D., Q. Y. Zhang, J. Y. Riou, and B. G. Spratt. 1994. Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin resistance in N. meningitidis: natural events and laboratory simulation. J. Bacteriol. 176:333-337.
39. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
40. Bradford, P. A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J. J. Rahal, S. Brooks, S. Cebular, and J. Quale. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 b-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
41. Bradford, P. A., C. E. Cherubin, V. Idemyor, B. A. Rasmussen, and K. Bush. 1994. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrob. Agents Chemother. 38:761-766.
42. Bradley, S. J., A. L. Wilson, M. C. Allen, H. A. Sher, A. H. Goldstone, and G. M. Scott. 1999. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J. Antimicrob. Chemother. 43:261-266.
43. Brenner, D. G., and J. R. Knowles. 1981. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 α- and 6 β-monodeuterio and of 6,6-dideuterio derivatives with RTEM β-lactamase from Escherichia coli. Biochemistry 20:3680-3687.
44. Brenner, D. G., and J. R. Knowles. 1984. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM β-lactamase from Escherichia coli. Biochemistry 23:5833-5839.
45. Broom, N. J. P., T. H. Farmer, N. F. Osborne, and J. W. Tyler. 1992. Studies on the mechanism of action of (5R)-(Z)-6-(1-methyl-1,2,3-triazol- 4-ylmethylene) penem-3-carboxylic acid (BRL 42715), a potent inhibitor of bacterial β-lactamase. J. Chem. Soc. Chem. Commun. 1992:1663-1664.
46. Brown, A. G. 1986. Clavulanic acid, a novel β-lactamase inhibitor - a case study in drug discovery and development. Drug Des. Deliv. 1:1-21.
47. Brown, R. P., R. T. Aplin, and C. J. Schofield. 1996. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35: 12421-12432.
48. Budzikiewicz, H. 2001. Siderophore-antibiotic conjugates used as Trojan horses against Pseudomonas aeruginosa. Curr. Top. Med. Chem. 1:73-82.
49. Bulychev, A., J. Bellettini, M. O'Brien, P. J. Crocker, J. P. Samama, M. J. Miller, and S. Mobashery. 2000. N-Sulfonyloxy-β-lactam inhibitors for β-lactamases. Tetrahedron 56:5719-5728.
50. Bulychev, A., I. Massova, K. Miyashita, and S. Mobashery. 1997. Nuances of mechanisms and their implications for evolution of the versatile β-lactamase activity: from biosynthetic enzymes to drug resistance factors. J. Am. Chem. Soc. 119:7619-7625.
51. Bush, K. 1998. Metallo-β-lactamases: a class apart. Clin. Infect. Dis. 27(Suppl. 1):S48-S53.
52. Bush, K. 1988. β-Lactamase inhibitors from laboratory to clinic. Clin. Microbiol. Rev. 1:109-123.
53. Bush, K. 1986. Evaluation of enzyme inhibition data in screening for new drugs. Drugs Exp. Clin. Res. 12:565-576.
54. Bush, K., and P. A. Bradford. 2007. β-Lactamases: historical perspectives, p. 67-79. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
55. Bush, K., J. S. Freudenberger, and R. B. Sykes. 1982. Interaction of azthreonam and related monobactams with β-lactamases from gram-negative bacteria. Antimicrob. Agents Chemother. 22:414-420.
56. Bush, K., and G. A. Jacoby. 2009. An updated functional clssification of β-lactamases. Antimicrob. Agents Chemother. [Epub ahead of print.] doi: 10.1128/AAC.01009-09.
57. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
58. Bush, K., C. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
59. Bush, L. M., and C. C. Johnson. 2000. Ureidopenicillins and β-lactam/β-lactam inhibitor combinations. Infect. Dis. Clin. North Am. 14:409-433.
60. Buynak, J. D. 2006. Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations. Biochem. Pharmacol. 71:930-940.
61. Buynak, J. D., H. Chen, L. Vogeti, V. R. Gadhachanda, C. A. Buchanan, T. Palzkill, R. W. Shaw, J. Spencer, and T. R. Walsh. 2004. Penicillin-derived inhibitors that simultaneously target both metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 14:1299-1304.
62. Buynak, J. D., V. R. Doppalapudi, and G. Adam. 2000. The synthesis and evaluation of 3-substituted-7-(alkylidene)cephalosporin sulfones as β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 10:853-857.
63. Buynak, J. D., A. S. Rao, V. R. Doppalapudi, G. Adam, P. J. Petersen, and S. D. Nidamarthy. 1999. The synthesis and evaluation of 6-alkylidene-2′β-substituted penam sulfones as β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 9:1997-2002.
64. 3 substituent. Bioorg. Med. Chem. Lett. 12:1663-1666.
65. Buynak, J. D., K. Wu, B. Bachmann, D. Khasnis, L. Hua, H. K. Nguyen, and C. L. Carver. 1995. Synthesis and biological activity of 7-alkylidenecephems. J. Med. Chem. 38:1022-1034.
66. Campoli-Richards, D. M., and R. N. Brogden. 1987. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 33:577-609.
67. Canton, R., and T. M. Coque. 2006. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol. 9:466-475.
68. Canton, R., M. I. Morosini, O. Martin, S. de la Maza, and E. G. de la Pedrosa. 2008. IRT and CMT β-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14(Suppl. 1):53-62.
69. Cartwright, S. J., and A. F. Coulson. 1979. A semi-synthetic penicillinase inactivator. Nature 278:360-361.
70. Caselli, E., R. A. Powers, L. C. Blasczcak, C. Y. Wu, F. Prati, and B. K. Shoichet. 2001. Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases. Chem. Biol. 8:17-31.
71. Centers for Disease Control. 1982. Global distribution of penicillinase-producing Neisseria gonorrhoeae (PPNG). MMWR Morb. Mortal. Wkly. Rep. 31:1-3.
72. Chaibi, E. B., S. Farzaneh, A. Morand, J. Peduzzi, M. Barthelemy, D. Sirot, and R. Labia. 1996. Problems encountered in the characterization of IRT β-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin. J. Antimicrob. Chemother. 37:190-191.
73. Chaibi, E. B., J. Peduzzi, S. Farzaneh, M. Barthelemy, D. Sirot, and R. Labia. 1998. Clinical inhibitor-resistant mutants of the β-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. Biochim. Biophys. Acta 1382:38-46.
74. Chaibi, E. B., D. Sirot, G. Paul, and R. Labia. 1999. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43:447-458.
75. Chakraborty, R., E. Storey, and D. van der Helm. 2007. Molecular mechanism of ferricsiderophore passage through the outer membrane receptor proteins of Escherichia coli. Biometals 20:263-274.
76. Chambers, H. F. 1999. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J. Infect. Dis. 179(Suppl. 2):S353-S359.
77. Chardon, H., S. Farzaneh, R. Labia, V. Jarlier, M. H. Nicolas, G. Paul, C. Poyart, D. Sirot, and J. Sirot. 1995. Analysis of β-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to coamoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group. J. Antimicrob. Chemother. 36:267-269.
78. Charnas, R. L., J. Fisher, and J. R. Knowles. 1978. Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry 17:2185-2189.
79. Charnas, R. L., and J. R. Knowles. 1981. Inactivation of RTEM β-lactamase from Escherichia coli by clavulanic acid and 9-deoxyclavulanic acid. Biochemistry 20:3214-3219.
80. Charnas, R. L., and J. R. Knowles. 1981. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid. Biochemistry. 20:2732-2737.
81. Chen, C. C., and O. Herzberg. 1992. Inhibition of β-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies. J. Mol. Biol. 224:1103-1113.
82. Chen, C. C., J. Rahil, R. F. Pratt, and O. Herzberg. 1993. Structure of a phosphonate-inhibited β-lactamase. An analog of the tetrahedral transition state/intermediate of β-lactam hydrolysis. J. Mol. Biol. 234:165-178.
83. Chen, Y., J. Delmas, J. Sirot, B. Shoichet, and R. Bonnet. 2005. Atomic resolution structures of CTX-M β-lactamases: extended spectrum activities from increased mobility and decreased stability. J. Mol. Biol. 348:349-362.
84. Chen, Y., G. Minasov, T. A. Roth, F. Prati, and B. K. Shoichet. 2006. The deacylation mechanism of AmpC β-lactamase at ultrahigh resolution. J. Am. Chem. Soc. 128:2970-2976.
85. Chen, Y., B. Shoichet, and R. Bonnet. 2005. Structure, function, and inhibition along the reaction coordinate of CTX-M β-lactamases. J. Am. Chem. Soc. 127:5423-5434.
86. Cherry, P. C., C. E. Newall, and N. S. Weston. 1978. Preparation of the 7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-2-ene system and the reversible cleavage of its oxazoline ring. J. Chem. Soc. Chem. Commun. 1978:469-470.
87. Coleman, K., D. R. Griffin, J. W. Page, and P. A. Upshon. 1989. In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. 33:1580-1587.
88. Concha, N. O., C. A. Janson, P. Rowling, S. Pearson, C. A. Cheever, B. P. Clarke, C. Lewis, M. Galleni, J. M. Frere, D. J. Payne, J. H. Bateson, and S. S. Abdel-Meguid. 2000. Crystal structure of the IMP-1 metallo-β-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry 39:4288-4298.
89. Conrath, K. E., M. Lauwereys, M. Galleni, A. Matagne, J. M. Frere, J. Kinne, L. Wyns, and S. Muyldermans. 2001. β-Lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45:2807-2812.
90. Copar, A., T. Prevec, B. Anzic, T. Mesar, L. Selic, M. Vilar, and T. Solmajer. 2002. Design, synthesis and bioactivity evaluation of tribactam β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 12:971-975.
91. Copar, A., T. Solmajer, B. Anzie, T. Kuzman, T. Mesar, and D. Kocjan. December 2002. Ethylidene derivatives of tricyclic carbapenems. U.S. patent 6,489,318.
92. Copeland, R. A. 2005. Evaluation of enzyme inhibitors in drug discovery. John Wiley & Sons, Inc., New York, NY.
93. Corvec, S., L. Poirel, E. Espaze, C. Giraudeau, H. Drugeon, and P. Nordmann. 2008. Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme. J. Hosp. Infect. 68:73-82.
94. Crichlow, G. V., M. Nukaga, V. R. Doppalapudi, J. D. Buynak, and J. R. Knox. 2001. Inhibition of class C β-lactamases: structure of a reaction intermediate with a cephem sulfone. Biochemistry 40:6233-6239.
95. Crompton, I. E., B. K. Cuthbert, G. Lowe, and S. G. Waley. 1988. β-lactamase inhibitors. The inhibition of serine β-lactamases by specific boronic acids. Biochem. J. 251:453-459.
96. Crowder, M. W., J. Spencer, and A. J. Vila. 2006. Metallo-β-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39: 721-728.
97. Daiyasu, H., K. Osaka, Y. Ishino, and H. Toh. 2001. Expansion of the zinc metallo-hydrolase family of the β-lactamase fold. FEBS Lett. 503:1-6.
98. Danel, F., M. G. Page, and D. M. Livermore. 2007. Class D β-lactamases, p. 163-194. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
99. Danel, F., and M. G. P. Page. 2007. Inhibition of AmpC β-lactamase by monobactams, abstr. F-126. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
100. Datta, N., and P. Kontomichalou. 1965. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208:239-241.
101. Delaire, M., R. Labia, J. P. Samama, and J. M. Masson. 1992. Site-directed mutagenesis at the active site of Escherichia coli TEM-1 β-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis. J. Biol. Chem. 267:20600- 20606.
102. Desarbre, E., A. DeFontage, M. G. P. Page, F. Richalet, and P. Roussel. 2007. Antimicrobial activity of novel monobactams, abstr. F1-351. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. 103. Diaz, N., T. L. Sordo, K. M. Merz Jr., and D. Suarez. 2003. Insights into the acylation mechanism of class A β-lactamases from molecular dynamics simulations of the TEM-1 enzyme complexed with benzylpenicillin. J. Am. Chem. Soc. 125:672-684.
103. Docquier, J., T. Stachyra, M. Benvenuti, G. M. Rossolini, S. Mangani, M. C. Pechereau, J. M. Bruneau, M. Claudon, F. Barbosa, C. Miossec, and M. T. Black. 2009. High resolution crystal structure of CTX-M-15 in complex with the new β-lactamase inhibitor NXL104, abstr. C1-1098. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. 105. Doran, J. L., B. K. Leskiw, S. Aippersbach, and S. E. Jensen. 1990. Isolation and characterization of a β-lactamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene. J. Bacteriol. 172:4909-4918.
104. Doumith, M., M. J. Ellington, D. M. Livermore, and N. Woodford. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63:659-667.
105. Dowson, C. G., A. Hutchison, N. Woodford, A. P. Johnson, R. C. George, and B. G. Spratt. 1990. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc. Natl. Acad. Sci. U. S. A. 87: 5858-5862.
106. Drawz, S. M., M. Babic, C. R. Bethel, M. Taracila, A. M. Distler, C. Ori, E. Caselli, F. Prati, and R. A. Bonomo. Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry. [Epub ahead of print.] doi:10.1021/bi9015988.
107. Drawz, S. M., C. R. Bethel, K. M. Hujer, K. N. Hurless, A. M. Distler, E. Caselli, F. Prati, and R. A. Bonomo. 2009. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV β-lactamase: a study of Ambler position Asn276. Biochemistry. 48:4557-4566.
108. Dubois, V., L. Poirel, C. Arpin, L. Coulange, C. Bebear, P. Nordmann, and C. Quentin. 2004. SHV-49, a novel inhibitor-resistant β-lactamase in a clinical isolate of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:4466-4469.
109. Dubois, V., L. Poirel, F. Demarthe, C. Arpin, L. Coulange, L. A. Minarini, M. C. Bezian, P. Nordmann, and C. Quentin. 2008. Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant β-lactamase from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52:3792-3794
110. Dubus, A., P. Ledent, J. Lamotte-Brasseur, and J. M. Frere. 1996. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins 25:473-485.
111. Dubus, A., J. M. Wilkin, X. Raquet, S. Normark, and J. M. Frere. 1994. Catalytic mechanism of active-site serine β-lactamases: role of the conserved hydroxy group of the Lys-Thr(Ser)-Gly triad. Biochem. J. 30:485-494.
112. Durkin, J. P., and T. Viswanatha. 1978. Clavulanic acid inhibition of β-lactamase I from Bacillus cereus 569/H. J. Antibiot. (Tokyo) 31:1162-1169.
113. Easton, C. J., and J. R. Knowles. 1982. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid. Biochemistry 21:2857-2862.
114. Elwell, L. P., J. De Graaff, D. Seibert, and S. Falkow. 1975. Plasmid-linked ampicillin resistance in Haempohilus influenza type b. Infect. Immun. 12: 404-410.
115. Endimiani, A., Y. Choudhary, and R. A. Bonomo. 2009. In vitro activity of NXL104 in combination with β-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
116. Endimiani, A., Y. Doi, C. R. Bethel, M. Taracila, J. M. Adams-Haduch, A. O'Keefe, A. M. Hujer, D. L. Paterson, M. J. Skalweit, M. G. Page, S. M. Drawz, and R. A. Bonomo. 2009. Enhancing resistance to cephalosporins in class C β-lactamases: impact of Gly116Glu in CMY-2. Biochemistry. [Epub ahead of print.] doi:10.1021/bi9015549.
117. Endimiani, A., A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, D. J. Diekema, G. S. Hall, S. G. Jenkins, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA. J. Antimicrob. Chemother. 63:427-437.
118. English, A. R., J. A. Retsema, A. E. Girard, J. E. Lynch, and W. E. Barth. 1978. CP-45,899, a β-lactamase inhibitor that extends the antibacterial spectrum of β-lactams: initial bacteriological characterization. Antimicrob. Agents Chemother. 14:414-419.
119. Falagas, M. E., P. E. Valkimadi, Y. T. Huang, D. K. Matthaiou, and P. R. Hsueh. 2008. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62:889-894.
120. Farmer, T. H., J. W. Page, D. J. Payne, and D. J. Knowles. 1994. Kinetic and physical studies of β-lactamase inhibition by a novel penem, BRL 42715. Biochem. J. 303:825-830.
121. Farzaneh, S., E. B. Chaibi, J. Peduzzi, M. Barthelemy, R. Labia, J. Blazquez, and F. Baquero. 1996. Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob. Agents Chemother. 40:2434-2436.
122. Fisher, J., J. G. Belasco, R. L. Charnas, S. Khosla, and J. R. Knowles. 1980. β-Lactamase inactivation by mechanism-based reagents. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289:309-319.
123. Fisher, J., R. L. Charnas, S. M. Bradley, and J. R. Knowles. 1981. Inactivation of the RTEM β-lactamase from Escherichia coli. Interaction of penam sulfones with enzyme. Biochemistry. 20:2726-2731.
124. Fisher, J., R. L. Charnas, and J. R. Knowles. 1978. Kinetic studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry 17:2180-2184.
125. Fisher, J. F., S. O. Meroueh, and S. Mobashery. 2005. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:395-424.
126. Fisher, J. F., and S. Mobashery. 2009. Three decades of the class A β-lactamase acyl-enzyme. Curr. Protein Pept. Sci. 10:401-407.
127. Foulds, G., W. E. Barth, J. R. Bianchine, A. R. English, D. Girard, S. L. Hayes, M. O'Brien, and P. Somani. 1980. Pharmacokinetics of CP-45.899 and pro-drug CP-47.904 in animals and humans, p. 353-356. In J. D. Nelson and C. Grassi (ed.), Current chemotherapy and infectious disease. American Society for Microbiology, Washington DC.
128. Fuchs, P. C., A. L. Barry, C. Thornsberry, and R. N. Jones. 1984. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob. Agents Chemother. 25:392-394.
129. Galleni, M., G. Amicosante, and J. M. Frere. 1988. A survey of the kinetic parameters of class C β-lactamases. Cephalosporins and other β-lactam compounds. Biochem. J. 255:123-129.
130. Galleni, M., and J. M. Frere. 2007. Kinetics of β-lactamases and pencillin-binding proteins, p. 195-213. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
131. Galleni, M., J. Lamotte-Brasseur, G. M. Rossolini, J. Spencer, O. Dideberg, and J. M. Frere. 2001. Standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 45:660-663.
132. Ganta, S. R., S. Perumal, S. R. Pagadala, O. Samuelsen, J. Spencer, R. F. Pratt, and J. D. Buynak. 2009. Approaches to the simultaneous inactivation of metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 19:1618-1622.
133. Garau, G., C. Bebrone, C. Anne, M. Galleni, J. M. Frere, and O. Dideberg. 2005. A metallo-β-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J. Mol. Biol. 345:785-795.
134. Garau, G., I. Garcia-Saez, C. Bebrone, C. Anne, P. Mercuri, M. Galleni, J. M. Frere, and O. Dideberg. 2004. Update of the standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 48:2347-2349.
135. Gaucher, B., C. Dantier, E. Desarbre, and M. G. P. Page. 2007. Novel monoand bicyclic monobactams as potent inhibitors of class C β-lactamases, abstr. F1-310. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
136. Gavin, P. J., M. T. Suseno, R. B. Thomson, Jr., J. M. Gaydos, C. L. Pierson, D. C. Halstead, J. Aslanzadeh, S. Brecher, C. Rotstein, S. E. Brossette, and L. R. Peterson. 2006. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob. Agents Chemother. 50:2244-2247.
137. Gherman, B. F., S. D. Goldberg, V. W. Cornish, and R. A. Friesner. 2004. Mixed quantum mechanical/molecular mechanical (QM/MM) study of the deacylation reaction in a penicillin binding protein (PBP) versus in a class C β-lactamase. J. Am. Chem. Soc. 126:7652-7664.
138. Giakkoupi, P., E. Tzelepi, N. J. Legakis, and L. S. Tzouvelekis. 1999. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 β-lactamases. J. Antimicrob. Chemother. 43:23-29.
139. Giakkoupi, P., E. Tzelepi, N. J. Legakis, and L. S. Tzouvelekis. 1998. Substitution of Arg-244 by Cys or Ser in SHV-1 and SHV-5 β-lactamases confers resistance to mechanism-based inhibitors and reduces catalytic efficiency of the enzymes. FEMS Microbiol. Lett. 160:49-54.
140. Gibson, R. M., H. Christensen, and S. G. Waley. 1990. Site-directed mutagenesis of β-lactamase I. Single and double mutants of Glu-166 and Lys-73. Biochem. J. 272:613-619.
141. Gin, A., L. Dilay, J. A. Karlowsky, A. Walkty, E. Rubinstein, and G. G. Zhanel. 2007. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev. Anti-Infect. Ther. 5:365-383.
142. Girlich, D., A. Karim, L. Poirel, M. H. Cavin, C. Verny, and P. Nordmann. 2000. Molecular epidemiology of an outbreak due to IRT-2 β-lactamaseproducing strains of Klebsiella pneumoniae in a geriatric department. J. Antimicrob. Chemother. 45:467-473.
143. Girlich, D., T. Naas, and P. Nordmann. 2004. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48:2043-2048.
144. Goffin, C., and J. M. Ghuysen. 1998. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. 62:1079-1093.
145. Golemi, D., L. Maveyraud, A. Ishiwata, S. Tranier, K. Miyashita, T. Nagase, I. Massova, L. Mourey, J. P. Samama, and S. Mobashery. 2000. 6-(Hydroxyalkyl)penicillinates as probes for mechanisms of β-lactamases. J. Antibiot. (Tokyo) 53:1022-1027.
146. Golemi, D., L. Maveyraud, S. Vakulenko, J. P. Samama, and S. Mobashery. 2001. Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases. Proc. Natl. Acad. Sci. U. S. A. 98:14280-14285.
147. Gorbach, S. L. 1994. Antibiotic treatment of anaerobic infections. Clin. Infect. Dis. 18(Suppl. 4):S305-310.
148. Guillaume, G., M. Vanhove, J. Lamotte-Brasseur, P. Ledent, M. Jamin, B. Joris, and J. M. Frere. 1997. Site-directed mutagenesis of glutamate 166 in two β-lactamases. Kinetic and molecular modeling studies. J. Biol. Chem. 272:5438-5444.
149. Hanes, M. S., K. M. Jude, J. M. Berger, R. A. Bonomo, and T. M. Handel. 2009. Structural and biochemical characterization of the interaction between KPC-2 β-lactamase and β-lactamase inhibitor protein. Biochemistry 48:9185-9193.
150. Hanson, N. D., and C. C. Sanders. 1999. Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5:881-894.
151. Hardy, L. W., and J. F. Kirsch. 1984. Diffusion-limited component of reactions catalyzed by Bacillus cereus β-lactamase I. Biochemistry 23:1275-1282.
152. Hashizume, T., A. Yamaguchi, T. Hirata, and T. Sawai. 1984.
153. Hedstrom, S. A. 1984. Treatment with β-lactam antibiotics in skin and soft tissue infections. Scand. J. Infect. Dis. Suppl. 42:135-142.
154. Heinze-Krauss, I., P. Angehrn, R. L. Charnas, K. Gubernator, E. M. Gutknecht, C. Hubschwerlen, M. Kania, C. Oefner, M. G. Page, S. Sogabe, J. L. Specklin, and F. Winkler. 1998. Structure-based design of β-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J. Med. Chem. 41:3961-3971.
155. Helfand, M. S., C. R. Bethel, A. M. Hujer, K. M. Hujer, V. E. Anderson, and R. A. Bonomo. 2003. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278:52724-52729.
156. Helfand, M. S., and R. A. Bonomo. 2005. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum β-lactamases and metallo-β-lactamases on the treatment of resistant Gram-negative pathogens. Curr. Opin. Pharmacol. 5:452-458.
157. Helfand, M. S., A. M. Hujer, F. D. Sonnichsen, and R. A. Bonomo. 2002. Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV β-lactamase. J. Biol. Chem. 277:47719-47723.
158. Helfand, M. S., M. A. Taracila, L. Borgianni, J. Docquier, A. M. Venkatesan, and T. S. Mansour. 2007. Inhibition of class A, B and C β-lactamases by bicyclic 6-methylidene penems via Michaelis complexes and cyclic enamines, abstr. C1-94. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
159. Helfand, M. S., M. A. Taracila, M. A. Totir, R. A. Bonomo, J. D. Buynak, F. van den Akker, and P. R. Carey. 2007. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a β-lactamase that confers resistance to clinical inhibitors. Biochemistry 46:8689-8699.
160. Helfand, M. S., M. A. Totir, M. P. Carey, A. M. Hujer, R. A. Bonomo, and P. R. Carey. 2003. Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 42:13386-13392.
161. Henquell, C., C. Chanal, D. Sirot, R. Labia, and J. Sirot. 1995. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 39:427-430.
162. Henquell, C., D. Sirot, C. Chanal, C. De Champs, P. Chatron, B. Lafeuille, P. Texier, J. Sirot, and R. Cluzel. 1994. Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J. Antimicrob. Chemother. 34:707-714.
163. Heritier, C., L. Poirel, D. Aubert, and P. Nordmann. 2003. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother. 47:268-273.
164. Heritier, C., L. Poirel, T. Lambert, and P. Nordmann. 2005. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:3198-3202.
165. Hermann, J. C., C. Hensen, L. Ridder, A. J. Mulholland, and H. D. Holtje. 2005. Mechanisms of antibiotic resistance: QM/MM modeling of the acylation reaction of a class A β-lactamase with benzylpenicillin. J. Am. Chem. Soc. 127:4454-4465.
166. Hernandez Valladares, M., A. Felici, G. Weber, H. W. Adolph, M. Zeppezauer, G. M. Rossolini, G. Amicosante, J. M. Frere, and M. Galleni. 1997. Zn(II) dependence of the Aeromonas hydrophila AE036 metallo-β-lactamase activity and stability. Biochemistry 36:11534-11541.
167. Hernandez Valladares, M., M. Kiefer, U. Heinz, R. P. Soto, W. Meyer-Klaucke, H. F. Nolting, M. Zeppezauer, M. Galleni, J. M. Frere, G. M. Rossolini, G. Amicosante, and H. W. Adolph. 2000. Kinetic and spectroscopic characterization of native and metal-substituted β-lactamase from Aeromonas hydrophila AE036. FEBS Lett. 467:221-225.
168. Herzberg, O., and J. Moult. 1987. Bacterial resistance to β-lactam antibiotics: crystal structure of β-lactamase from Staphylococcus aureus PC1 at 2.5 A resolution. Science 236:694-701.
169. Higgins, P. G., H. Wisplinghoff, D. Stefanik, and H. Seifert. 2004. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 48:1586-1592.
170. Hollingsworth, J. A., J. F. Donohoe, R. Hone, and P. J. Keelan. 1984. Clinical experience with aztreonam in urinary and respiratory tract infections. Curr. Med. Res. Opin. 9:316-322.
171. Hopkins, J. M., and K. J. Towner. 1990. Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes. J. Antimicrob. Chemother. 25:49-55.
172. Horsfall, L. E., G. Garau, B. M. Lienard, O. Dideberg, C. J. Schofield, J. M. Frere, and M. Galleni. 2007. Competitive inhibitors of the CphA metallo-β-lactamase from Aeromonas hydrophila. Antimicrob. Agents Chemother. 51:2136-2142.
173. Hubschwerlen, C., P. Angehrn, K. Gubernator, M. G. Page, and J. L. Specklin. 1998. Structure-based design of β-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. J. Med. Chem. 41:3972-3975.
174. Hugonnet, J. E., L. W. Tremblay, H. I. Boshoff, C. E. Barry III, and J. S. Blanchard. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218.
175. Hujer, A. M., E. Desarbre, A. Endimiani, D. L. Paterson, M. G. P. Page, and R. A. Bonomo. 2007. Activity of BAL30376 against multidrug resistant (MDR) Klebsiella and Acinetobacter spp., abstr. F1-333a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
176. Hujer, A. M., K. M. Hujer, and R. A. Bonomo. 2001. Mutagenesis of amino acid residues in the SHV-1 β-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547:37-50.
177. Hujer, K. M., A. M. Hujer, E. A. Hulten, S. Bajaksouzian, J. M. Adams, C. J. Donskey, D. J. Ecker, C. Massire, M. W. Eshoo, R. Sampath, J. M. Thomson, P. N. Rather, D. W. Craft, J. T. Fishbain, A. J. Ewell, M. R. Jacobs, D. L. Paterson, and R. A. Bonomo. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50:4114-4123.
178. Ibuka, A. S., Y. Ishii, M. Galleni, M. Ishiguro, K. Yamaguchi, J. M. Frere, H. Matsuzawa, and H. Sakai. 2003. Crystal structure of extended-spectrum β-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 42:10634-10643.
179. Ikonomidis, A., D. Tokatlidou, I. Kristo, D. Sofianou, A. Tsakris, P. Mantzana, S. Pournaras, and A. N. Maniatis. 2005. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-β-lactamase gene. J. Clin. Microbiol. 43:5344-5347.
180. Imada, A., K. Kitano, K. Kintaka, M. Muroi, and M. Asai. 1981. Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin. Nature 289:590-591.
181. Imtiaz, U., E. M. Billings, J. R. Knox, E. K. Manavathu, S. A. Lerner, and S. Mobashery. 1993. Inactivation of class A β-lactamases by clavulanic acid: the role of Arginine 244 in a proposed noncerted sequence of events. J. Am. Chem. Soc. 115:4435-4442.
182. Imtiaz, U., E. M. Billings, J. R. Knox, and S. Mobashery. 1994. A structure-based analysis of the inhibition of class A β-lactamases by sulbactam. Biochemistry 33:5728-5738.
183. Imtiaz, U., E. K. Manavathu, S. A. Lerner, and S. Mobashery. 1993. Critical hydrogen bonding by serine 235 for cephalosporinase activity of TEM-1 b-lactamase. Antimicrob. Agents Chemother. 37:2438-2442.
184. Jacob, F., B. Joris, S. Lepage, J. Dusart, and J. M. Frere. 1990. Role of the conserved amino acids of the 'SDN' loop (Ser130, Asp131 and Asn132) in a class A β-lactamase studied by site-directed mutagenesis. Biochem. J. 271:399-406.
185. Jacobs, C., J. M. Frere, and S. Normark. 1997. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β-lactam resistance in gram-negative bacteria. Cell 88:823-832.
186. Jacoby, G. A. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
187. Jacoby, G. A., and I. Carreras. 1990. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 34:858-862.
188. Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35:1697-1704.
189. Jacoby, G. A., D. M. Mills, and N. Chow. 2004. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:3203-3206.
190. Jacoby, G. A., and L. S. Munoz-Price. 2005. The new β-lactamases. N Engl. J. Med. 352:380-391.
191. Jamieson, C. E., P. A. Lambert, and I. N. Simpson. 2003. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother. 47:2615-2618.
192. Jamieson, C. E., P. A. Lambert, and I. N. Simpson. 2003. In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother. 47:1652-1657.
193. Jelsch, C., L. Mourey, J. M. Masson, and J. P. Samama. 1993. Crystal structure of Escherichia coli TEM1 β-lactamase at 1.8 A resolution. Proteins 16:364-383.
194. Jones, R. N., M. A. Pfaller, P. C. Fuchs, K. Aldridge, S. D. Allen, and E. H. Gerlach. 1989. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12:489-494.
195. Juan, C., O. Gutierrez, A. Oliver, J. I. Ayestaran, N. Borrell, and J. L. Perez. 2005. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infect. 11:887-892.
196. Kaczmarek, F. S., T. D. Gootz, F. Dib-Hajj, W. Shang, S. Hallowell, and M. Cronan. 2004. Genetic and molecular characterization of β-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin. Antimicrob. Agents Chemother. 48:1630-1639.
197. Kalp, M., and P. R. Carey. 2008. Carbapenems and SHV-1 β-lactamase form different acyl-enzyme populations in crystals and solution. Biochemistry 47:11830-11837.
198. Kalp, M., A. Sheri, J. D. Buynak, C. R. Bethel, R. A. Bonomo, and P. R. Carey. 2007. Efficient inhibition of class A and class D β-lactamases by Michaelis complexes. J. Biol. Chem. 282:21588-21591.
199. Kalp, M., M. A. Totir, J. D. Buynak, and P. R. Carey. 2009. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 β-lactamases: Raman crystallographic evidence. J. Am. Chem. Soc. 131:2338-2347.
200. Kaye, K. S., H. S. Gold, M. J. Schwaber, L. Venkataraman, Y. Qi, P. C. De Girolami, M. H. Samore, G. Anderson, J. K. Rasheed, and F. C. Tenover. 2004. Variety of β-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob. Agents Chemother. 48:1520-1525.
201. Kaye, K. S., A. D. Harris, H. Gold, and Y. Carmeli. 2000. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob. Agents Chemother. 44:1004-1009.
202. Ke, W., C. R. Bethel, J. M. Thomson, R. A. Bonomo, and F. van den Akker. 2007. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry 46:5732-5740.
203. Kiener, P. A., and S. G. Waley. 1978. Reversible inhibitors of penicillinases. Biochem. J. 169:197-204.
204. Kirby, W. M. 1944. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99:452-453.
205. Kitzis, M. D., B. Ferre, A. Coutrot, J. F. Acar, and L. Gutmann. 1989. In vitro activity of combinations of β-lactam antibiotics with β-lactamase inhibitors against cephalosporinase-producing bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 8:783-788.
206. Knothe, H., P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11:315-317.
207. Knott-Hunziker, V., S. Petursson, S. G. Waley, B. Jaurin, and T. Grundstrom. 1982. The acyl-enzyme mechanism of β-lactamase action. The evidence for class C β-lactamases. Biochem. J. 207:315-322.
208. Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601.
209. Knox, J. R., P. C. Moews, W. A. Escobar, and A. L. Fink. 1993. A catalytically-impaired class A β-lactamase: 2 A crystal structure and kinetics of the Bacillus licheniformis E166A mutant. Protein Eng. 6:11-18.
210. Kropp, H., L. Gerckens, J. G. Sundelof, and F. M. Kahan. 1985. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev. Infect. Dis. 7(Suppl. 3):S389-S410.
211. Kuzin, A. P., M. Nukaga, Y. Nukaga, A. Hujer, R. A. Bonomo, and J. R. Knox. 2001. Inhibition of the SHV-1 β-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 40:1861-1866.
212. Kuzin, A. P., M. Nukaga, Y. Nukaga, A. M. Hujer, R. A. Bonomo, and J. R. Knox. 1999. Structure of the SHV-1 β-lactamase. Biochemistry 38:5720-5727.
213. Labia, R., A. Morand, and J. Peduzzi. 1986. Timentin and β-lactamases. J. Antimicrob. Chemother. 17(Suppl. C):17-26.
214. Laible, G., B. G. Spratt, and R. Hakenbeck. 1991. Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Mol. Microbiol. 5:1993-2002.
215. Lakaye, B., A. Dubus, S. Lepage, S. Groslambert, and J. M. Frere. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with β-lactams. Mol. Microbiol. 31:89-101.
216. Lamotte-Brasseur, J., G. Dive, O. Dideberg, P. Charlier, J. M. Frere, and J. M. Ghuysen. 1991. Mechanism of acyl transfer by the class A serine β-lactamase of Streptomyces albus G. Biochem. J. 279:213-221.
217. Lan, C. K., P. R. Hsueh, W. W. Wong, C. P. Fung, Y. T. Lau, J. Y. Yeung, G. T. Young, and C. C. Su. 2003. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum β-lactamase-producing organisms. J. Microbiol. Immunol. Infect. 36:182-186.
218. Landman, D., M. Chockalingam, and J. M. Quale. 1999. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin. Infect. Dis. 28:1062-1066.
219. Laraki, N., N. Franceschini, G. M. Rossolini, P. Santucci, C. Meunier, E. de Pauw, G. Amicosante, J. M. Frere, and M. Galleni. 1999. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-β-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43:902-906.
220. Leflon-Guibout, V., V. Speldooren, B. Heym, and M. Nicolas-Chanoine. 2000. Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of blaTEM genes. Antimicrob. Agents Chemother. 44:2709-2714.
221. Leflon-Guibout, V., G. Ternat, B. Heym, and M. H. Nicolas-Chanoine. 2002. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J. Antimicrob. Chemother. 49:367-371.
222. Lenfant, F., R. Labia, and J. M. Masson. 1991. Replacement of lysine 234 affects transition state stabilization in the active site of β-lactamase TEM1. J. Biol. Chem. 266:17187-17194.
223. Levasseur, P., A. Girard, L. Lavallade, C. Miossec, D. M. Shlaes, M. T. Black, J. L. Pace, and K. Coleman. 2009. Efficacy of ceftazidime/NXL104 combination in murine septicaemia caused by CTX-M-producing Enterobacteriaceae species, abstr. A1-005. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
224. Levin, A. S. 2002. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin. Microbiol. Infect. 8:144-153.
225. Li, N., and R. F. Pratt. 1998. Inhibition of serine β-lactamases by acyl phosph(on)ates: a new source of inert acyl [and phosphyl] enzymes. J. Chem. Soc. 120:4264-4268.
226. Li, X. Z., D. Ma, D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 38:1742-1752.
227. Li, X. Z., H. Nikaido, and K. Poole. 1995. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1948-1953.
228. Li, X. Z., L. Zhang, and K. Poole. 2000. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45:433-436.
229. Lienard, B. M., G. Garau, L. Horsfall, A. I. Karsisiotis, C. Damblon, P. Lassaux, C. Papamicael, G. C. Roberts, M. Galleni, O. Dideberg, J. M. Frere, and C. J. Schofield. 2008. Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols. Org. Biomol. Chem. 6:2282-2294.
230. Lienard, B. M., R. Huting, P. Lassaux, M. Galleni, J. M. Frere, and C. J. Schofield. 2008. Dynamic combinatorial mass spectrometry leads to metallo-β-lactamase inhibitors. J. Med. Chem. 51:684-688.
231. Lin, S., M. Thomas, S. Mark, V. Anderson, and R. A. Bonomo. 1999. OHIO-1 β-lactamase mutants: the Arg244Ser mutant and resistance to β-lactams and β-lactamase inhibitors. Biochim. Biophys. Acta 1432:125-136.
232. Lindquist, R. N., and C. Terry. 1974. Inhibition of subtilisin by boronic acids, potential analogs of tetrahedral reaction intermediates. Arch. Biochem. Biophys. 160:135-144.
233. Lister, P. D., V. M. Gardner, and C. C. Sanders. 1999. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob. Agents Chemother. 43:882-889.
234. Livermore, D. M. 1998. β-lactamase-mediated resistance and opportunities for its control. J. Antimicrob. Chemother. 41(Suppl. D):25-41.
235. Livermore, D. M. 1987. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur. J. Clin. Microbiol. 6:439-445.
236. Livermore, D. M. 1993. Determinants of the activity of β-lactamase inhibitor combinations. J. Antimicrob. Chemother. 31(Suppl. A):9-21.
237. Livermore, D. M. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046-2048.
238. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.
239. Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and β-lactamase induction. J. Antimicrob. Chemother. 24(Suppl. B):23-33.
240. Livermore, D. M., and H. Y. Chen. 1997. Potentiation of β-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases. J. Antimicrob. Chemother. 40:335-343.
241. Livermore, D. M., R. Hope, S. Mushtaq, and M. Warner. 2008. Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers. Clin. Microbiol. Infect. 14(Suppl. 1):189-193.
242. Livermore, D. M., S. Mushtaq, M. Warner, C. Miossec, and N. Woodford. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
243. Lobkovsky, E., E. M. Billings, P. C. Moews, J. Rahil, R. F. Pratt, and J. R. Knox. 1994. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry 33:6762-6772.
244. Lodise, T. P., Jr., B. Lomaestro, K. A. Rodvold, L. H. Danziger, and G. L. Drusano. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724.
245. Majumdar, S., S. A. Adediran, M. Nukaga, and R. F. Pratt. 2005. Inhibition of class D β-lactamases by diaroyl phosphates. Biochemistry 44:16121-16129.
246. Majumdar, S., and R. F. Pratt. 2009. Inhibition of class A and C β-lactamases by diaroyl phosphates. Biochemistry 48:8285-8292.
247. Majumdar, S., and R. F. Pratt. 2009. Intramolecular cooperativity in the reaction of diacyl phosphates with serine β-lactamases. Biochemistry 48: 8293-8298.
248. Reference deleted.
249. Martinez, J. L., E. Cercenado, M. Rodriguez-Creixems, M. F. Vincente-Perez, A. Delgado-Iribarren, and F. Baquero. 1987. Resistance to β-lactam/clavulanate. Lancet ii:1473.
250. Martinez, J. L., M. F. Vicente, A. Delgado-Iribarren, J. C. Perez-Diaz, and F. Baquero. 1989. Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob. Agents Chemother. 33:595.
251. Massova, I., and S. Mobashery. 1998. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob. Agents Chemother. 42:1-17.
252. Matagne, A., P. Ledent, D. Monnaie, A. Felici, M. Jamin, X. Raquet, M. Galleni, D. Klein, I. Francois, and J. M. Frere. 1995. Kinetic study of interaction between BRL 42715, β-lactamases, and D-alanyl-D-alanine peptidases. Antimicrob. Agents Chemother. 39:227-231.
253. Matthew, M., R. W. Hedges, and J. T. Smith. 1979. Types of β-lactamase determined by plasmids in gram-negative bacteria. J. Bacteriol. 138:657-662.
254. Maveyraud, L., D. Golemi-Kotra, A. Ishiwata, O. Meroueh, S. Mobashery, and J. P. Samama. 2002. High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 β-lactamase. J. Am. Chem. Soc. 124:2461-2465.
255. Maveyraud, L., D. Golemi, L. P. Kotra, S. Tranier, S. Vakulenko, S. Mobashery, and J. P. Samama. 2000. Insights into class D β-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure 8:1289-1298.
256. Maveyraud, L., I. Massova, C. Birck, K. Miyashita, J. P. Samama, and S. Mobashery. 1996. Crystal structure of 6 α-(hydroxymethyl) penicillanate complexed to the TEM-1 β-lactamase from Escherichia coli: evidence on the mechanism of action of a novel inhibitor designed by a computer-aided process. J. Am. Chem. Soc. 118:7435-7440.
257. Maveyraud, L., L. Mourey, L. P. Kotra, J.-D. Pedelacq, V. Guillet, and S. Mobashery. 1998. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from the antibiotic-resistant bacteria. J. Am. Chem. Soc. 120:9748-9752.
258. Medeiros, A. A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24(Suppl. 1):S19-S45.
259. Mendelman, P. M., D. O. Chaffin, and G. Kalaitzoglou. 1990. Penicillinbinding proteins and ampicillin resistance in Haemophilus influenzae. J. Antimicrob. Chemother. 25:525-534.
260. Mendonca, N., V. Manageiro, F. Robin, M. J. Salgado, E. Ferreira, M. Canica, and R. Bonnet. 2008. The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. Antimicrob. Agents Chemother. 52:1806-1811.
261. Merdjan, H., A. Girard, C. Miossec, M. Robertson, and P. Levasseur. 2009. Pharmacokinetics and efficacy of ceftazidime / NXL104 combination in a murine pneumonia model caused by an AmpC-producing Klebsiella pneumoniae, abstr. A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
262. Meroueh, S., J. Cha, and S. Mobashery. 2007. Inhibition of class A β-lactamases, p. 101-114. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzymemediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washingtion, DC.
263. Meroueh, S. O., J. F. Fisher, H. B. Schlegel, and S. Mobashery. 2005. Ab initio QM/MM study of class A β-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. J. Am. Chem. Soc. 127:15397-15407.
264. Meroueh, S. O., P. Roblin, D. Golemi, L. Maveyraud, S. B. Vakulenko, Y. Zhang, J. P. Samama, and S. Mobashery. 2002. Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM β-lactamase from Escherichia coli. J. Am. Chem. Soc. 124:9422-9430.
265. Michaux, C., P. Charlier, J. M. Frere, and J. Wouters. 2005. Crystal structure of BRL 42715, C6-(N1-methyl-1,2,3-triazolylmethylene)penem, in complex with Enterobacter cloacae 908R β-lactamase: evidence for a stereoselective mechanism from docking studies. J. Am. Chem. Soc. 127:3262-3263.
266. Miller, J. M., C. N. Baker, and C. Thornsberry. 1978. Inhibition of β-lactamase in Neisseria gonorrhoeae by sodium clavulanate. Antimicrob. Agents Chemother. 14:794-796.
267. Minasov, G., X. Wang, and B. K. Shoichet. 2002. An ultrahigh resolution structure of TEM-1 β-lactamase suggests a role for Glu166 as the general base in acylation. J. Am. Chem. Soc. 124:5333-5340.
268. Miro, E., F. Navarro, B. Mirelis, M. Sabate, A. Rivera, P. Coll, and G. Prats. 2002. Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. Antimicrob. Agents Chemother. 46:3991-3994.
269. Moews, P. C., J. R. Knox, O. Dideberg, P. Charlier, and J. M. Frere. 1990. β-lactamase of Bacillus licheniformis 749/C at 2 A resolution. Proteins 7:156-171.
270. Mollard, C., C. Moali, C. Papamicael, C. Damblon, S. Vessilier, G. Amicosante, C. J. Schofield, M. Galleni, J. M. Frere, and G. C. Roberts. 2001. Thiomandelic acid, a broad spectrum inhibitor of zinc β-lactamases: kinetic and spectroscopic studies. J. Biol. Chem. 276:45015-45023.
271. Moloughney, J. G., J. D. Thomas, and J. H. Toney. 2005. Novel IMP-1 metallo-β-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol. Lett. 243:65-71.
272. Monks, J., and S. G. Waley. 1988. Imipenem as substrate and inhibitor of β-lactamases. Biochem. J. 253:323-328.
273. Monnaie, D., A. Dubus, and J. M. Frere. 1994. The role of lysine-67 in a class C β-lactamase is mainly electrostatic. Biochem. J. 302:1-4.
274. Morandi, F., E. Caselli, S. Morandi, P. J. Focia, J. Blazquez, B. K. Shoichet, and F. Prati. 2003. Nanomolar inhibitors of AmpC β-lactamase. J. Am. Chem. Soc. 125:685-695.
275. Mourey, L., L. P. Kotra, J. Bellettini, A. Bulychev, M. O'Brien, M. J. Miller, S. Mobashery, and J. P. Samama. 1999. Inhibition of the broad spectrum nonmetallocarbapenamase of class A (NMC-A) β-lactamase from Enterobacter cloacae by monocyclic β-lactams. J. Biol. Chem. 274:25260-25265.
276. Mourey, L., K. Miyashita, P. Swaren, A. Bulychev, J. P. Samama, and S. Mobashery. 1998. Inhibition of the NMC-A β-lactamase by a penicillanic acid derivative and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme. J. Am. Chem. Soc. 120:9382-9383.
277. Muder, R. R. 2007. Optimizing therapy for Stenotrophomonas maltophilia. Semin. Respir. Crit. Care Med. 28:672-677.
278. OXA-53) and 6′-N-aminoglycoside acetyltransferase genes [aac(6′)-I30]. J. Antimicrob. Chemother. 54:354-359.
279. Murphy, B. P., and R. F. Pratt. 1988. Evidence for an oxyanion hole in serine β-lactamases and DD-peptidases. Biochem. J. 256:669-672.
280. Mussi, M. A., A. S. Limansky, and A. M. Viale. 2005. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of β-barrel outer membrane proteins. Antimicrob. Agents Chemother. 49:1432-1440.
281. Naas, T., and P. Nordmann. 1999. OXA-type β-lactamases. Curr. Pharm. Des. 5:865-879.
282. Naas, T., L. Poirel, and P. Nordmann. 2008. Minor extended-spectrum β-lactamases. Clin. Microbiol. Infect. 14(Suppl. 1):42-52.
283. Nagano, R., Y. Adachi, T. Hashizume, and H. Morishima. 2000. In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1β-methylcarbapenem, against transferable IMP-1 metallo-β-lactamase producers. J. Antimicrob. Chemother. 45:271-276.
284. Nagano, R., Y. Adachi, H. Imamura, K. Yamada, T. Hashizume, and H. Morishima. 1999. Carbapenem derivatives as potential inhibitors of various β-lactamases, including class B metallo-β-lactamases. Antimicrob. Agents Chemother. 43:2497-2503.
285. Naumovski, L., J. P. Quinn, D. Miyashiro, M. Patel, K. Bush, S. B. Singer, D. Graves, T. Palzkill, and A. M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob. Agents Chemother. 36:1991-1996.
286. Nauton, L., R. Kahn, G. Garau, J. F. Hernandez, and O. Dideberg. 2008. Structural insights into the design of inhibitors for the L1 metallo-β-lactamase from Stenotrophomonas maltophilia. J. Mol. Biol. 375:257-269.
287. Neu, H. C., and K. P. Fu. 1978. Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrob. Agents Chemother. 14:650-655.
288. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382-388.
289. Nikaido, H. 1998. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access? Drug Resist. Updat. 1:93-98.
290. Nikaido, H., W. Liu, and E. Y. Rosenberg. 1990. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34:337-342.
291. Nishida, K., C. Kunugita, T. Uji, F. Higashitani, A. Hyodo, N. Unemi, S. N. Maiti, O. A. Phillips, P. Spevak, K. P. Atchison, S. M. Salama, H. Atwal, and R. G. Micetich. 1999. In vitro and in vivo activities of Syn2190, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. 43:1895-1900.
292. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
293. Nordmann, P., S. Mariotte, T. Naas, R. Labia, and M. H. Nicolas. 1993. Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob. Agents Chemother. 37:939-946.
294. Nordmann, P., and L. Poirel. 2002. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8:321-331.
295. Nuesch-Inderbinen, M. T., H. Hachler, and F. H. Kayser. 1995. New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV β-lactamases. Antimicrob. Agents Chemother. 39:1726-1730.
296. Nukaga, M., T. Abe, A. M. Venkatesan, T. S. Mansour, R. A. Bonomo, and J. R. Knox. 2003. Inhibition of class A and class C β-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Biochemistry 42:13152-13159.
297. Nukaga, M., C. R. Bethel, J. M. Thomson, A. M. Hujer, A. Distler, V. E. Anderson, J. R. Knox, and R. A. Bonomo. 2008. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc. 130:12656-12662.
298. Reference deleted.
299. Nukaga, M., S. Kumar, K. Nukaga, R. F. Pratt, and J. R. Knox. 2004. Hydrolysis of third-generation cephalosporins by class C β-lactamases. Structures of a transition state analog of cefotaxime in wild-type and extended spectrum enzymes. J. Biol. Chem. 279:9344-9352.
300. Nukaga, M., K. Mayama, A. M. Hujer, R. A. Bonomo, and J. R. Knox. 2003. Ultrahigh resolution structure of a class A β-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328:289-301.
301. Oefner, C., A. D'Arcy, J. J. Daly, K. Gubernator, R. L. Charnas, I. Heinze, C. Hubschwerlen, and F. K. Winkler. 1990. Refined crystal structure of β-lactamase from Citrobacter freundii indicates a mechanism for β-lactam hydrolysis. Nature 343:284-288.
302. Oliphant, A. R., and K. Struhl. 1989. An efficient method for generating proteins with altered enzymatic properties: application to β-lactamase. Proc. Natl. Acad. Sci. U. S. A. 86:9094-9098.
303. Oliver, A., M. Perez-Vazquez, M. Martinez-Ferrer, F. Baquero, L. De Rafael, and R. Canton. 1999. Ampicillin-sulbactam and amoxicillin- clavulanate susceptibility testing of Escherichia coli isolates with different betalactam resistance phenotypes. Antimicrob. Agents Chemother. 43:862-867.
304. Oliver, A., L. M. Weigel, J. K. Rasheed, J. E. McGowan Juniorperiod, Jr., P. Raney, and F. C. Tenover. 2002. Mechanisms of decreased
305. Olsen, L., S. Jost, H. W. Adolph, I. Pettersson, L. Hemmingsen, and F. S. Jorgensen. 2006. New leads of metallo-β-lactamase inhibitors from structure-based pharmacophore design. Bioorg. Med. Chem. 14:2627-2635.
306. Orencia, M. C., J. S. Yoon, J. E. Ness, W. P. Stemmer, and R. C. Stevens. 2001. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8:238-242.
307. Osuna, J., H. Viadiu, A. L. Fink, and X. Soberon. 1995. Substitution of Asp for Asn at position 132 in the active site of TEM β-lactamase. Activity toward different substrates and effects of neighboring residues. J. Biol. Chem. 270:775-780.
308. Oteo, J., A. Delgado-Iribarren, D. Vega, V. Bautista, M. C. Rodriguez, M. Velasco, J. M. Saavedra, M. Perez-Vazquez, S. Garcia-Cobos, L. Martinez-Martinez, and J. Campos. 2008. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int. J. Antimicrob. Agents 32:534-537.
309. Padayatti, P. S., M. S. Helfand, M. A. Totir, M. P. Carey, P. R. Carey, R. A. Bonomo, and F. van den Akker. 2005. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 β-lactamase. J. Biol. Chem. 280:34900-34907.
310. Padayatti, P. S., M. S. Helfand, M. A. Totir, M. P. Carey, A. M. Hujer, P. R. Carey, R. A. Bonomo, and F. van den Akker. 2004. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 β-lactamase: 1.63 A crystal structure. Biochemistry 43:843-848.
311. Padayatti, P. S., A. Sheri, M. A. Totir, M. S. Helfand, M. P. Carey, V. E. Anderson, P. R. Carey, C. R. Bethel, R. A. Bonomo, J. D. Buynak, and F. van den Akker. 2006. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J. Am. Chem. Soc. 128:13235-13242.
312. Paetzel, M., F. Danel, L. de Castro, S. C. Mosimann, M. G. Page, and N. C. Strynadka. 2000. Crystal structure of the class D β-lactamase OXA-10. Nat. Struct. Biol. 7:918-925.
313. Pagan-Rodriguez, D., X. Zhou, R. Simmons, C. R. Bethel, A. M. Hujer, M. S. Helfand, Z. Jin, B. Guo, V. E. Anderson, L. M. Ng, and R. A. Bonomo. 2004. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser1303Gly SHV-1 β-lactamase: insights into the mechanism of inhibition. J. Biol. Chem. 279:19494-19501.
314. Page, M. G. 2000. β-Lactamase inhibitors. Drug Resist. Updat. 3:109-125.
315. Page, M. G. 2007. Resistance mediated by penicllin-binding proteins, p. 81-99. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for Inhibition. ASM Press, Washington, DC.
316. Page, M. G., and J. Heim. 2009. New molecules from old classes: revisiting the development of β-lactams. Drugs 12:561-565.
317. Page, M. G., and J. Heim. 2009. Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol. 9:558-565.
318. Page, M. G. P., E. Desarbre, C. Geier, and B. Hofer. 2007. Activity of monobactam β-lactamase inhibitor combinations against β-lactam-resistant gram-negative bacteria, abstr. F1-311. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
319. Page, M. G. P., C. Mueller, B. Hofer, and E. Desarbre. 2009. Bactericidal effect of the novel siderophore monobactam BAL30072, abstr. P1111. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland.
320. Page, M. I., P. S. Hinchliffe, J. M. Wood, L. P. Harding, and A. P. Laws. 2003. Novel mechanism of inhibiting β-lactamases by sulfonylation using β-sultams. Bioorg. Med. Chem. Lett. 13:4489-4492.
321. Paisley, J. W., and J. A. Washington, 2nd. 1978. Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli. Antimicrob. Agents Chemother. 14:224-227.
322. Papp-Wallace, K. M., C. R. Bethel, A. Distler, C. Kasuboski, M. Taracila, and R. A. Bonomo. 2009. Inhibitor resistance in the KPC-2 β-lactamase: a pre-eminent property of this class A β-lactamase. Antimicrob. Agents Chemother. [Epub ahead of print.] doi:10.1128/AAC.00693-09.
323. Paterson, D. L. 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 34:S20-S28. (Discussion, S64-S73.)
324. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
325. Pattanaik, P., C. R. Bethel, A. M. Hujer, K. M. Hujer, A. M. Distler, M. Taracila, V. E. Anderson, T. R. Fritsche, R. N. Jones, S. R. Pagadala, F. van den Akker, J. D. Buynak, and R. A. Bonomo. 2009. Strategic design of an effective β-lactamase inhibitor: LN-1-255, a 6-alkylidene-2′- substituted penicillin sulfone. J. Biol. Chem. 284:945-953.
326. Patterson, J. E., T. C. Hardin, C. A. Kelly, R. C. Garcia, and J. H. Jorgensen. 2000. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 21:455-458.
327. Paukner, S., L. Hesse, A. Prezelj, T. Solmajer, and U. Urleb. 2009. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum β-lactamase inhibitor. Antimicrob. Agents Chemother. 53:505-511.
328. Paul-Soto, R., R. Bauer, J. M. Frere, M. Galleni, W. Meyer-Klaucke, H. Nolting, G. M. Rossolini, D. de Seny, M. Hernandez-Valladares, M. Zeppezauer, and H. W. Adolph. 1999. Mono- and binuclear Zn2+-β-lactamase. Role of the conserved cysteine in the catalytic mechanism. J. Biol. Chem. 274:13242-13249.
329. Paul-Soto, R., M. Hernandez-Valladares, M. Galleni, R. Bauer, M. Zeppezauer, J. M. Frere, and H. W. Adolph. 1998. Mono- and binuclear Zn-β-lactamase from Bacteroides fragilis: catalytic and structural roles of the zinc ions. FEBS Lett. 438:137-140.
330. Payne, D. J., J. H. Bateson, B. C. Gasson, D. Proctor, T. Khushi, T. H. Farmer, D. A. Tolson, D. Bell, P. W. Skett, A. C. Marshall, R. Reid, L. Ghosez, Y. Combret, and J. Marchand-Brynaert. 1997. Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol ester derivatives. Antimicrob. Agents Chemother. 41:135-140.
331. Payne, D. J., R. Cramp, D. J. Winstanley, and D. J. Knowles. 1994. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob. Agents Chemother. 38:767-772.
332. Payne, D. J., J. A. Hueso-Rodriguez, H. Boyd, N. O. Concha, C. A. Janson, M. Gilpin, J. H. Bateson, C. Cheever, N. L. Niconovich, S. Pearson, S. Rittenhouse, D. Tew, E. Diez, P. Perez, J. De La Fuente, M. Rees, and A. Rivera-Sagredo. 2002. Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-β-lactamases. Antimicrob. Agents Chemother. 46:1880-1886.
333. Pelto, R. B., and R. F. Pratt. 2008. Kinetics and mechanism of inhibition of a serine β-lactamase by O-aryloxycarbonyl hydroxamates. Biochemistry 47: 12037-12046.
334. Perez-Moreno, M. O., M. Perez-Moreno, M. Carulla, C. Rubio, A. M. Jardi, and J. Zaragoza. 2004. Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain). Clin. Microbiol. Infect. 10:234-241.
335. Perez, F., A. Endimiani, K. M. Hujer, and R. A. Bonomo. 2007. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7:459-469.
336. Perez, F., A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
337. Pernot, L., F. Frenois, T. Rybkine, G. L'Hermite, S. Petrella, J. Delettre, V. Jarlier, E. Collatz, and W. Sougakoff. 2001. Crystal structures of the class D β-lactamase OXA-13 in the native form and in complex with meropenem. J. Mol. Biol. 310:859-874.
338. Petersen, P. J., C. H. Jones, A. M. Venkatesan, T. S. Mansour, S. J. Projan, and P. A. Bradford. 2009. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem β-lactamase inhibitor BLI-489. Antimicrob. Agents Chemother. 53:370-384.
339. Peterson, L. R. 2008. Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin. Microbiol. Infect. 14(Suppl. 1):181-184.
340. Petit, A., L. Maveyraud, F. Lenfant, J. P. Samama, R. Labia, and J. M. Masson. 1995. Multiple substitutions at position 104 of β-lactamase TEM-1: assessing the role of this residue in substrate specificity. Biochem. J. 305:33-40.
341. Petrella, S., N. Ziental-Gelus, C. Mayer, M. Renard, V. Jarlier, and W. Sougakoff. 2008. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A β-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob. Agents Chemother. 52:3725-3736.
342. Pfaendler, H. R., F. Weisner, and K. Metzger. 1993. Synthesis and antibacterial activity of (1′R, 5R, 6R)-2-tert-butyl-6-(1′- hydroxyethyl)oxapenem-3-carboxylic acid. Bioorg. Med. Chem. Lett. 3:2211-2218.
343. Philippon, A., G. Arlet, and G. A. Jacoby. 2002. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
344. Philippon, A., R. Labia, and G. Jacoby. 1989. Extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 33:1131-1136.
345. Phillips, O. A., D. P. Czajkowski, P. Spevak, M. P. Singh, C. Hanehara-Kunugita, A. Hyodo, R. G. Micetich, and S. N. Maiti. 1997. SYN-1012: a new β-lactamase inhibitor of penem skeleton. J. Antibiot. (Tokyo) 50:350-356.
346. Pitout, J. D., and K. B. Laupland. 2008. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166.
347. Plantan, I., L. Selic, T. Mesar, P. S. Anderluh, M. Oblak, A. Prezelj, L. Hesse, M. Andrejasic, M. Vilar, D. Turk, A. Kocijan, T. Prevec, G. Vilfan, D. Kocjan, A. Copar, U. Urleb, and T. Solmajer. 2007. 4-Substituted trinems as broad spectrum β-lactamase inhibitors: structure-based design, synthesis, and biological activity. J. Med. Chem. 50:4113-4121.
348. Poirel, L., and P. Nordmann. 2002. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr. Pharm. Biotechnol. 3:117-127.
349. Poirel, L., and P. Nordmann. 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12:826-836.
350. Poole, K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26.
351. Potgieter, E., and L. J. Chalkley. 1995. Relatedness among penicillin-binding protein 2b genes of Streptococcus mitis, Streptococcus oralis, and Streptococcus pneumoniae. Microb. Drug Resist. 1:35-42.
352. Powers, R. A., J. Blazquez, G. S. Weston, M. I. Morosini, F. Baquero, and B. K. Shoichet. 1999. The complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamase. Protein Sci. 8:2330-2337.
353. Powers, R. A., E. Caselli, P. J. Focia, F. Prati, and B. K. Shoichet. 2001. Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40:9207-9214.
354. Powers, R. A., F. Morandi, and B. K. Shoichet. 2002. Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure 10:1013-1023.
355. Powers, R. A., and B. K. Shoichet. 2002. Structure-based approach for binding site identification on AmpC β-lactamase. J. Med. Chem. 45:3222-3234.
356. Pratt, R. F. 1989. Inhibition of a class C β-lactamase by a specific phosphonate monoester. Science 246:917-919.
357. Prezelj, A., A. Plantan, G. Vilfan, P. Stefanic Anderluh, L. Selic, P. Iglicar, V. Car, S. Andrensek, I. Legen, P. Smrdel, M. Cerne, U. Urleb, I. Locatelli, A. Mrhar, and N. Kovacic. 2007. Stability of 10-ethylidene trinems, PK of LK-157 and design of pro-drug esters, abstr. F1-0882. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
358. Quale, J., D. Landman, G. Saurina, E. Atwood, V. DiTore, and K. Patel. 1996. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin. Infect. Dis. 23:1020-1025.
359. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458.
360. Queenan, A. M., W. Shang, M. Kania, M. G. Page, and K. Bush. 2007. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51:3089-3095.
361. Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 41:223-232.
362. Rasmussen, B. A., K. Bush, D. Keeney, Y. Yang, R. Hare, C. O'Gara, and A. A. Medeiros. 1996. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother. 40:2080-2086.
363. Reading, C., and M. Cole. 1977. Clavulanic acid: a β-lactamase-inhibiting β-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 11:852-857.
364. Rebuck, J. A., K. M. Olsen, P. D. Fey, K. L. Bergman, and M. E. Rupp. 2000. In vitro activities of parenteral β-lactam antimicrobials against TEM-10-, TEM-26- and SHV-5-derived extended-spectrum β-lactamases expressed in an isogenic Escherichia coli host. J. Antimicrob. Chemother. 46:461-464.
365. Retsema, J. A., A. R. English, A. Girard, J. E. Lynch, M. Anderson, L. Brennan, C. Cimochowski, J. Faiella, W. Norcia, and P. Sawyer. 1986. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev. Infect. Dis. 8(Suppl. 5):S528-S534.
366. Reynolds, K. A., J. M. Thomson, K. D. Corbett, C. R. Bethel, J. M. Berger, J. F. Kirsch, R. A. Bonomo, and T. M. Handel. 2006. Structural and computational characterization of the SHV-1 β-lactamase-β-lactamase inhibitor protein interface. J. Biol. Chem. 281:26745-26753.
367. Rice, L. B. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197:1079-1081.
368. Rice, L. B., E. C. Eckstein, J. DeVente, and D. M. Shlaes. 1996. Ceftazidimeresistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin. Infect. Dis. 23:118-124.
369. Richmond, M. 1981. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of β-lactamases from clinically relevant bacterial species. J. Antimicrob. Chemother. 7:279-285.
370. Richter, H. G., P. Angehrn, C. Hubschwerlen, M. Kania, M. G. Page, J. L. Specklin, and F. K. Winkler. 1996. Design, synthesis, and evaluation of 2 β-alkenyl penam sulfone acids as inhibitors of β-lactamases. J. Med. Chem. 39:3712-3722.
371. Rizwi, I., A. K. Tan, A. L. Fink, and R. Virden. 1989. Clavulanate inactivation of Staphylococcus aureus β-lactamase. Biochem. J. 258:205-209.
372. Robin, F., J. Delmas, C. Chanal, D. Sirot, J. Sirot, and R. Bonnet. 2005. TEM-109 (CMT-5), a natural complex mutant of TEM-1 β-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob. Agents Chemother. 49:4443-4447.
373. Rodriguez-Bano, J., M. D. Navarro, L. Romero, M. A. Muniain, M. de Cueto, M. J. Rios, J. R. Hernandez, and A. Pascual. 2006. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43:1407-1414.
374. Roth, T. A., G. Minasov, S. Morandi, F. Prati, and B. K. Shoichet. 2003. Thermodynamic cycle analysis and inhibitor design against β-lactamase. Biochemistry 42:14483-14491.
375. Roy, C., C. Segura, M. Tirado, R. Reig, M. Hermida, D. Teruel, and A. Foz. 1985. Frequency of plasmid-determined β-lactamases in 680 consecutively isolated strains of Enterobacteriaceae. Eur. J. Clin. Microbiol. 4:146-147.
376. Saito, K., H. Yoneyama, and T. Nakae. 1999. nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome. FEMS Microbiol. Lett. 179:67-72.
377. Sandanayaka, V. P., G. B. Feigelson, A. S. Prashad, Y. Yang, and P. J. Petersen. 2001. Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 11:997-1000.
378. Sandanayaka, V. P., and Y. Yang. 2000. Dipolar cycloaddition of novel 6-(nitrileoxidomethyl) penam sulfone: an efficient route to a new class of β-lactamase inhibitors. Org. Lett. 2:3087-3090.
379. Sanders, C. C., J. P. Iaconis, G. P. Bodey, and G. Samonis. 1988. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob. Agents Chemother. 32:1365-1369.
380. Sauvage, E., F. Kerff, M. Terrak, J. A. Ayala, and P. Charlier. 2008. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32:234-258.
381. Saves, I., O. Burlet-Schiltz, P. Swaren, F. Lefevre, J. M. Masson, J. C. Prome, and J. P. Samama. 1995. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. J. Biol. Chem. 270:18240-18245.
382. Schneider, K. D., C. R. Bethel, A. M. Distler, A. M. Hujer, R. A. Bonomo, and D. A. Leonard. 2009. Mutation of the active site carboxy-lysine (K70) of OXA-1 β-lactamase results in a deacylation-deficient enzyme. Biochemistry 48:6136-6145.
383. Schneider, K. D., M. E. Karpen, R. A. Bonomo, D. A. Leonard, and R. A. Powers. 2009. The 1.4 Å crystal structure of the class D β-lactamase OXA-1 complexed with doripenem. Biochemistry 48:11840-11847.
384. Sham, D., C. Pillar, N. Brown, V. Alluru, C. Miossec, and P. Levasseur. 2009. Activity of ceftazidime/NXL104 and select comparators against geographically diverse clinical isolates of Pseudomonas aeruginosa, abstr. E-194. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
385. Shen, D., P. Winokur, and R. N. Jones. 2001. Characterization of extended spectrum β-lactamase-producing Klebsiella pneumoniae from Beijing, China. Int. J. Antimicrob. Agents 18:185-188.
386. Shimamura, T., A. Ibuka, S. Fushinobu, T. Wakagi, M. Ishiguro, Y. Ishii, and H. Matsuzawa. 2002. Acyl-intermediate structures of the extendedspectrum class A β-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. J. Biol. Chem. 277:46601-46608.
387. Shoichet, B. K., W. A. Baase, R. Kuroki, and B. W. Matthews. 1995. A relationship between protein stability and protein function. Proc. Natl. Acad. Sci. U. S. A. 92:452-456.
388. Siemann, S., D. P. Evanoff, L. Marrone, A. J. Clarke, T. Viswanatha, and G. I. Dmitrienko. 2002. N-Arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-β-lactamase. Antimicrob. Agents Chemother. 46:2450-2457.
389. Sirot, D., C. Chanal, R. Bonnet, C. De Champs, and L. Bret. 2001. Inhibitor-resistant TEM-33 β-lactamase in a Shigella sonnei isolate. Antimicrob. Agents Chemother. 45:2179-2180.
390. Sirot, D., C. Recule, E. B. Chaibi, L. Bret, J. Croize, C. Chanal-Claris, R. Labia, and J. Sirot. 1997. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 41:1322-1325.
391. Slocombe, B., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, R. Sutherland, and A. R. White. 1984. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid, p. 29-49. In Progress and perspectives on β-lactamase inhibition: a review of Augmentin. Custom Communications: Postgraduate Medicine, New York, NY.
392. Sougakoff, W., G. L'Hermite, L. Pernot, T. Naas, V. Guillet, P. Nordmann, V. Jarlier, and J. Delettre. 2002. Structure of the imipenem-hydrolyzing class A β-lactamase SME-1 from Serratia marcescens. Acta Crystallogr. D Biol. Crystallogr. 58:267-274.
393. Srikumar, R., C. J. Paul, and K. Poole. 2000. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 182:1410-1414.
394. Stachyra, T., P. Levasseur, M. C. Pechereau, A. M. Girard, M. Claudon, C. Miossec, and M. T. Black. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329.
395. Stachyra, T., M. C. Pechereau, J. M. Bruneau, C. Miossec, J. M. Frere, and M. T. Black. 2009. The nature of inhibition of TEM-1 β-lactamase by the non-β-lactam inhibitor NXL104, abstr. C1-1374. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco. CA.
396. Strynadka, N. C., H. Adachi, S. E. Jensen, K. Johns, A. Sielecki, C. Betzel, K. Sutoh, and M. N. James. 1992. Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 A resolution. Nature 359:700-705.
397. Strynadka, N. C., S. E. Jensen, K. Johns, H. Blanchard, M. Page, A. Matagne, J. M. Frere, and M. N. James. 1994. Structural and kinetic characterization of a β-lactamase-inhibitor protein. Nature 368:657-660.
398. Strynadka, N. C., R. Martin, S. E. Jensen, M. Gold, and J. B. Jones. 1996. Structure-based design of a potent transition state analogue for TEM-1 β-lactamase. Nat. Struct. Biol. 3:688-695.
399. Studemeister, A. E., and J. P. Quinn. 1988. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob. Agents Chemother. 32:1267-1268.
400. Sulton, D., D. Pagan-Rodriguez, X. Zhou, Y. Liu, A. M. Hujer, C. R. Bethel, M. S. Helfand, J. M. Thomson, V. E. Anderson, J. D. Buynak, L. M. Ng, and R. A. Bonomo. 2005. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J. Biol. Chem. 280:35528-35536.
401. Sun, T., C. R. Bethel, R. A. Bonomo, and J. R. Knox. 2004. Inhibitor-resistant class A β-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant. Biochemistry 43:14111-14117.
402. Sun, T., M. Nukaga, K. Mayama, E. H. Braswell, and J. R. Knox. 2003. Comparison of β-lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci. 12:82-91.
403. Sun, T., M. Nukaga, K. Mayama, G. V. Crichlow, A. P. Kuzin, and J. R. Knox. 2001. Crystallization and preliminary X-ray study of OXA-1, a class D β-lactamase. Acta Crystallogr. D Biol. Crystallogr. 57:1912-1914.
404. Swaren, P., D. Golemi, S. Cabantous, A. Bulychev, L. Maveyraud, S. Mobashery, and J. P. Samama. 1999. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 β-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry 38:9570-9576.
405. Swaren, P., L. Maveyraud, V. Guillet, J. M. Masson, L. Mourey, and J. P. Samama. 1995. Electrostatic analysis of TEM1 β-lactamase: effect of substrate binding, steep potential gradients and consequences of site-directed mutations. Structure 3:603-613.
406. Swaren, P., L. Maveyraud, X. Raquet, S. Cabantous, C. Duez, J. D. Pedelacq, S. Mariotte-Boyer, L. Mourey, R. Labia, M. H. Nicolas-Chanoine, P. Nordmann, J. M. Frere, and J. P. Samama. 1998. X-ray analysis of the NMC-A β-lactamase at 1.64-A resolution, a class A carbapenemase with broad substrate specificity. J. Biol. Chem. 273:26714-26721.
407. Sykes, R. B., D. P. Bonner, K. Bush, and N. H. Georgopapadakou. 1982. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob. Agents Chemother. 21:85-92.
408. Sykes, R. B., D. P. Bonner, K. Bush, N. H. Georgopapadakou, and J. S. Wells. 1981. Monobactams-monocyclic β-lactam antibiotics produced by bacteria. J. Antimicrob. Chemother. 8(Suppl. E):1-16.
409. Sykes, R. B., C. M. Cimarusti, D. P. Bonner, K. Bush, D. M. Floyd, N. H. Georgopapadakou, W. M. Koster, W. C. Liu, W. L. Parker, P. A. Principe, M. L. Rathnum, W. A. Slusarchyk, W. H. Trejo, and J. S. Wells. 1981. Monocyclic β-lactam antibiotics produced by bacteria. Nature 291:489-491.
410. Tabei, K., X. Feng, A. M. Venkatesan, T. Abe, U. Hideki, T. S. Mansour, and M. M. Siegel. 2004. Mechanism of inactivation of β-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry. J. Med. Chem. 47:3674-3688.
411. Taibi, P., and S. Mobashery. 1995. Mechanism of turnover of imipenem by the TEM β-lactamase revisited. J. Am. Chem. Soc. 117:7600-7605.
412. Thomas, V. L., D. Golemi-Kotra, C. Kim, S. B. Vakulenko, S. Mobashery, and B. K. Shoichet. 2005. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM β-lactamase. Biochemistry 44:9330-9338.
413. Thomson, C. J., R. S. Miles, and S. G. Amyes. 1995. Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio. Antimicrob. Agents Chemother. 39:2591-2592.
414. Thomson, J. M., A. M. Distler, and R. A. Bonomo. 2007. Overcoming resistance to β-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244. Biochemistry 46:11361-11368.
415. Thomson, J. M., A. M. Distler, F. Prati, and R. A. Bonomo. 2006. Probing active site chemistry in SHV β-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J. Biol. Chem. 281:26734-26744.
416. Thomson, J. M., F. Prati, C. R. Bethel, and R. A. Bonomo. 2007. Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 51:1577-1579.
417. Tondi, D., F. Morandi, R. Bonnet, M. P. Costi, and B. K. Shoichet. 2005. Structure-based optimization of a non-β-lactam lead results in inhibitors that do not up-regulate β-lactamase expression in cell culture. J. Am. Chem. Soc. 127:4632-4639.
418. Toney, J. H., P. M. Fitzgerald, N. Grover-Sharma, S. H. Olson, W. J. May, J. G. Sundelof, D. E. Vanderwall, K. A. Cleary, S. K. Grant, J. K. Wu, J. W. Kozarich, D. L. Pompliano, and G. G. Hammond. 1998. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-β-lactamase. Chem. Biol. 5:185-196.
419. Toney, J. H., G. G. Hammond, P. M. Fitzgerald, N. Sharma, J. M. Balkovec, G. P. Rouen, S. H. Olson, M. L. Hammond, M. L. Greenlee, and Y. D. Gao. 2001. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-β-lactamase. J. Biol. Chem. 276:31913-31918.
420. Totir, M. A., P. S. Padayatti, M. S. Helfand, M. P. Carey, R. A. Bonomo, P. R. Carey, and F. van den Akker. 2006. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine β-lactamase intermediates. Biochemistry 45:11895-11904.
421. Tranier, S., A. T. Bouthors, L. Maveyraud, V. Guillet, W. Sougakoff, and J. P. Samama. 2000. The high resolution crystal structure for class A β-lactamase PER-1 reveals the bases for its increase in breadth of activity. J. Biol. Chem. 275:28075-28082.
422. Trehan, I., F. Morandi, L. C. Blaszczak, and B. K. Shoichet. 2002. Using steric hindrance to design new inhibitors of class C β-lactamases. Chem. Biol. 9:971-980.
423. Tsang, W. Y., N. Ahmed, P. S. Hinchliffe, J. M. Wood, L. P. Harding, A. P. Laws, and M. I. Page. 2005. Different transition-state structures for the reactions of β-lactams and analogous β-sultams with serine β-lactamases. J. Am. Chem. Soc. 127:17556-17564.
424. Tumbarello, M., T. Spanu, M. Sanguinetti, R. Citton, E. Montuori, F. Leone, G. Fadda, and R. Cauda. 2006. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50:498-504.
425. Tzouvelekis, L. S., and R. A. Bonomo. 1999. SHV-type β-lactamases. Curr. Pharm. Des. 5:847-864.
426. Tzouvelekis, L. S., M. Gazouli, E. E. Prinarakis, E. Tzelepi, and N. J. Legakis. 1997. Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against β-lactamases that belong to groups 1, 2b, and 2be. Antimicrob. Agents Chemother. 41:475-477.
427. Urban, C., E. Go, N. Mariano, B. J. Berger, I. Avraham, D. Rubin, and J. J. Rahal. 1993. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 167:448-451.
428. Urban, C., J. J. Rahal, and B. Luft. 1991. Effect of a β-lactamase inhibitor, tazobactam, on growth and penicillin-binding proteins of Borrelia burgdorferi. FEMS Microbiol. Lett. 66:113-116.
429. Usher, K. C., L. C. Blaszczak, G. S. Weston, B. K. Shoichet, and S. J. Remington. 1998. Three-dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry 37:16082-16092.
430. Vakulenko, S. B., B. Geryk, L. P. Kotra, S. Mobashery, and S. A. Lerner. 1998. Selection and characterization of β-lactam-β- lactamase inactivatorresistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene. Antimicrob. Agents Chemother. 42:1542-1548.
431. Vedel, G., A. Belaaouaj, L. Gilly, R. Labia, A. Philippon, P. Nevot, and G. Paul. 1992. Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. J. Antimicrob. Chemother. 30:449-462.
432. Venkatesan, A. M., A. Agarwal, T. Abe, H. Ushirogochi, I. Yamamura, M. Ado, T. Tsuyoshi, O. Dos Santos, Y. Gu, F. W. Sum, Z. Li, G. Francisco, Y. I. Lin, P. J. Petersen, Y. Yang, T. Kumagai, W. J. Weiss, D. M. Shlaes, J. R. Knox, and T. S. Mansour. 2006. Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum β-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods. J. Med. Chem. 49:4623-4637.
433. Venkatesan, A. M., Y. Gu, O. Dos Santos, T. Abe, A. Agarwal, Y. Yang, P. J. Petersen, W. J. Weiss, T. S. Mansour, M. Nukaga, A. M. Hujer, R. A. Bonomo, and J. R. Knox. 2004. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum β-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates. J. Med. Chem. 47:6556-6568.
434. Venturelli, A., D. Tondi, L. Cancian, F. Morandi, G. Cannazza, B. Segatore, F. Prati, G. Amicosante, B. K. Shoichet, and M. P. Costi. 2007. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J. Med. Chem. 50:5644-5654.
435. Vilar, M., M. Galleni, T. Solmajer, B. Turk, J. M. Frere, and A. Matagne. 2001. Kinetic study of two novel enantiomeric tricyclic β-lactams which efficiently inactivate class C β-lactamases. Antimicrob. Agents Chemother. 45:2215-2223.
436. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.
437. Walter, M. W., R. M. Adlington, J. E. Baldwin, and C. J. Schofield. 1997. Synthesis of metallo-β-lactamase inhibitors. Tetrahedron 53:7275-7290.
438. Walter, M. W., A. Felici, M. Galleni, R. P. Soto, R. M. Adlington, J. E. Baldwin, J. M. Frere, M. Gololobox, and C. J. Schofield. 1996. Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamases. Bioorg. Med. Chem. Lett. 6:2455-2458.
439. Walther-Rasmussen, J., and N. Hoiby. 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57:373-383.
440. Wang, X., G. Minasov, J. Blazquez, E. Caselli, F. Prati, and B. K. Shoichet. 2003. Recognition and resistance in TEM β-lactamase. Biochemistry 42:8434-8444.
441. Wang, X., G. Minasov, and B. K. Shoichet. 2002. Noncovalent interaction energies in covalent complexes: TEM-1 β-lactamase and β-lactams. Proteins 47:86-96.
442. Wang, X., G. Minasov, and B. K. Shoichet. 2002. The structural bases of antibiotic resistance in the clinically derived mutant β-lactamases TEM-30, TEM-32, and TEM-34. J. Biol. Chem. 277:32149-32156.
443. Wang, Z., W. Fast, and S. J. Benkovic. 1999. On the mechanism of the metallo-β-lactamase from Bacteroides fragilis. Biochemistry 38:10013-10023.
444. Wang, Z., W. Fast, A. M. Valentine, and S. J. Benkovic. 1999. Metallo-β-lactamase: structure and mechanism. Curr. Opin. Chem. Biol. 3:614-622.
445. Weiss, W. J., P. J. Petersen, T. M. Murphy, L. Tardio, Y. Yang, P. A. Bradford, A. M. Venkatesan, T. Abe, T. Isoda, A. Mihira, H. Ushirogochi, T. Takasake, S. Projan, J. O'Connell, and T. S. Mansour. 2004. In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother. 48:4589-4596.
446. Weiss, W. J., M. E. Pulse, A. Endimiani, K. M. Hujer, A. M. Hujer, and R. A. Bonomo. 2009. Efficacy of NXL104 in combination with ceftazidime in murine infection models, abstr. B-1339. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
447. Weston, G. S., J. Blazquez, F. Baquero, and B. K. Shoichet. 1998. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase. J. Med. Chem. 41:4577-4586.
448. Wexler, H. M., B. Harris, W. T. Carter, and S. M. Finegold. 1985. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob. Agents Chemother. 27:876-878.
449. Wilkinson, A. S., S. Ward, M. Kania, M. G. Page, and C. W. Wharton. 1999. Multiple conformations of the acylenzyme formed in the hydrolysis of methicillin by Citrobacter freundii β-lactamase: a time-resolved FTIR spectroscopic study. Biochemistry 38:3851-3856.
450. Williams, H., A. King, K. Shannon, and I. Phillips. 1988. Amoxycillin/clavulanate resistant Escherichia coli. Lancet i:304-305.
451. Williams, J. D. 1997. β-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin. Infect. Dis. 24:494-497.
452. Wu, P. J., K. Shannon, and I. Phillips. 1994. Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrob. Agents Chemother. 38:494-498.
453. Wu, P. J., K. Shannon, and I. Phillips. 1995. Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 36:927-939.
454. Wyrembak, P. N., K. Babaoglu, R. B. Pelto, B. K. Shoichet, and R. F. Pratt. 2007. O-Aryloxycarbonyl hydroxamates: new β-lactamase inhibitors that cross-link the active site. J. Am. Chem. Soc. 129:9548-9549.
455. Xu, D., D. Xie, and H. Guo. 2006. Catalytic mechanism of class B2 metallo-β-lactamase. J. Biol. Chem. 281:8740-8747.
456. Yamaguchi, Y., W. Jin, K. Matsunaga, S. Ikemizu, Y. Yamagata, J. Wachino, N. Shibata, Y. Arakawa, and H. Kurosaki. 2007. Crystallographic investigation of the inhibition mode of a VIM-2 metallo-β-lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor. J. Med. Chem. 50:6647-6653.
457. Yang, Y., K. Janota, K. Tabei, N. Huang, M. M. Siegel, Y. I. Lin, B. A. Rasmussen, and D. M. Shlaes. 2000. Mechanism of inhibition of the class A β-lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry. J. Biol. Chem. 275:26674-26682.
458. Yang, Y. J., P. J. Wu, and D. M. Livermore. 1990. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother. 34:755-758.
459. Yigit, H., A. M. Queenan, J. K. Rasheed, J. W. Biddle, A. Domenech-Sanchez, S. Alberti, K. Bush, and F. C. Tenover. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889.
460. Yuan, J., W. Huang, D. C. Chow, and T. Palzkill. 2009. Fine mapping of the sequence requirements for binding of β-lactamase inhibitory protein (BLIP) to TEM-1 β-lactamase using a genetic screen for BLIP function. J. Mol. Biol. 389:401-412.
461. Zafaralla, G., E. K. Manavathu, S. A. Lerner, and S. Mobashery. 1992. Elucidation of the role of Arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31:3847-3852.
462. 1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine-244 of class A β-lactamases during the course of turnover. J. Chem. Soc. 114:1505-1506.
463. Zapun, A., C. Contreras-Martel, and T. Vernet. 2008. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol. Rev. 32:361-385.
464. Zhang, Z., and T. Palzkill. 2004. Dissecting the protein-protein interface between β-lactamase inhibitory protein and class A β-lactamases. J. Biol. Chem. 279:42860-42866.